SCHEMBL845592

SCHEMBL845592

Cc1ccsc1C(=O)N1CCC[C@H]1C(=O)Nc1ccc(/C=C/c2ccc(NC(=O)[C@@H]3CCCN3C(=O)c3sccc3C)cc2)cc1

nearest known ligand 0.64

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.64
MAPT P10636 1/20 0.48
TSHR P16473 1/20 0.47
APOBEC3A P31941 1/20 0.47
APOBEC3G Q9HC16 1/20 0.47
ALDH1A1 P00352 3/20 0.47
MAPK1 P28482 2/20 0.47
HTT P42858 1/20 0.47
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
NPSR1 Q6W5P4 1/20 0.45
POLB P06746 1/20 0.45
NPC1 O15118 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.43
MEN1 O00255 1/20 0.43
TDP1 Q9NUW8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL845181 0.81 MAPT (0.69) MAPTTSHRAPOBEC3AAPOBEC3GALDH1A1
SCHEMBL845008 0.81 ALDH1A1 (0.54) KMT2AMAPTTSHRALDH1A1MAPK1
SCHEMBL845422 0.81 KMT2A (0.46) KMT2AMAPTTSHRALDH1A1MAPK1
SCHEMBL845598 0.81 RAB9A (0.46) KMT2AMAPTTSHRALDH1A1MAPK1
SCHEMBL845258 0.79 MAPK1 (0.60) KMT2ATSHRALDH1A1MAPK1HTT
SCHEMBL845295 0.79 KDM4E (0.61) KMT2ATSHRALDH1A1MAPK1HTT
SCHEMBL845089 0.79 TSHR (0.45) KMT2AMAPTTSHRALDH1A1MAPK1
SCHEMBL845774 0.78 CYP2C19 (0.49) KMT2ATSHRALDH1A1MAPK1HTT
SCHEMBL873200 0.78 RHOC (0.48) KMT2AMAPTALDH1A1MAPK1HTT
SCHEMBL845541 0.78 RHOC (0.49) KMT2AMAPTAPOBEC3AAPOBEC3GALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143288-B2 Inhibitors of HCV replication BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-27 US disclosed
US-8143288-B2 Inhibitors of HCV replication BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-27 US disclosed